// App-Quantinova.ai

914 : Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)

Researchers

Presenter

  • Maria Buti

Principal Investigators

  • Tatjana Stepanova

  • Mustafa K. Celen

  • Robert Flisiak

  • Stephen D. Ryder

  • Adrian Streinu-Cercel

  • Selim Gurel

  • John F. Flaherty

  • Anuj Gaggar

  • Vithika Suri

  • Shuyuan Mo

  • Mani Subramanian

  • Elena Nurmukhametova

  • Fabien Zoulim

  • Pietro Andreone

  • Patrick Marcellin

Medical Centers

  • Gilead Sciences, Inc., Foster City, CA

  • Hospital Universitario del Mar, Barcelona, Spain

  • Medscan Clinic, Moscow, Russian Federation

  • Hopital Beaujon, Clichy, France

  • Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Italy

  • Hopital de la Croix Rousse, Lyon, France

  • Infectious Clinical Hospital #1 of Moscow Healthcare Department, Moscow, Russian Federation

  • Uludag Universitesi Tip Fakultesi, Bursa, Turkey

  • University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Medical University in Bialystok, Bialystok, Poland

  • Dicle University Hospital Infectious Diseases, Diyarbakir, Turkey

Locations

  • United States

  • Spain

  • Russia

  • France

  • Italy

  • Turkey

  • Romania

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Osteoporosis

  • Hepatitis B

Biomarkers

  • Alanine transaminase

  • Angiomodulin

  • Creatinine

  • Human albumin

  • Hepatitis B e antigen

  • Serum hepatitis B virus DNA

Drug/Treatment

  • Tenofovir disoproxil fumarate

  • Tenofovir alafenamide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved